Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 EarningsZacks Investment Research • 08/06/25
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025GlobeNewsWire • 07/15/25
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®GlobeNewsWire • 07/01/25
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?Zacks Investment Research • 06/26/25
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 06/11/25
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid CancersGlobeNewsWire • 05/30/25
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 05/09/25
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?Zacks Investment Research • 05/08/25
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/01/25
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025GlobeNewsWire • 04/10/25
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell LymphomaGlobeNewsWire • 04/08/25
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell LymphomaGlobeNewsWire • 03/11/25
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 02/12/25
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/11/25
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/11/25
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025GlobeNewsWire • 01/22/25
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/16/25
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer PatientsGlobeNewsWire • 01/14/25
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025GlobeNewsWire • 01/07/25